Drug Trial Radar · NCT04868877
Phase 1/2 Study Evaluating MCLA-129, a Human Anti-EGFR, Anti-c-MET Bispecific Antibody, in Advanced NSCLC and Other Solid Tumors, Alone and in Combination
Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Terminated
Enrollment
194
Actual
Start
Apr 28, 2021
Primary completion
Oct 1, 2026
Study completion Oct 1, 2026
Sponsor
- Lead sponsor
- Merus B.V.Industry
- Sponsor type
- Industry
- First posted
- May 3, 2021
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A phase 1/2 open-label multicenter study will be performed with an initial dose escalation part to determine the MTD and/or the RP2D of MCLA-129 in monotherapy or in combination in patients with NSCLC, HNSCC, GC/GEJ, ESCC, or other solid tumors and who are treatment naïve or have progressed after receiving prior therapy for advanced/metastatic disease.
Conditions
- Non-Small Cell Lung Cancer Metastatic
- Gastric Cancer
- Esophageal Squamous Cell Carcinoma
- Head and Neck Squamous Cell Carcinoma
- Colorectal Cancer
Interventions
MCLA-129Drug
full length IgG1 bispecific antibody that specifically targets the receptor tyrosine kinases EGFR and c-MET
OsimertinibDrug
Approved, 3rd-generation EGFR-TKI
ChemotherapyDrug
administrated by IV infusion
Primary outcomes
What the sponsor says the trial is designed to measure.
- To determine the maximum tolerated dose (MTD) and/or recommended phase 2 dose (RP2D)Time frame: First 28 days of treatment
- To evaluate clinical activity, as assessed by ORRTime frame: From first dose until RECIST progression or initiation of an alternative treatment, whichever occurs first.
Locations
51 sites in 9 countries. Site status is shown where the registry gives one.
University of California, Irvine
Orange, California
Sarah Cannon Research Institute
Nashville, Tennessee
START Mountain Region
West Valley City, Utah
Next Oncology Virginia
Fairfax, Virginia
Institut Jules Bordet
Anderlecht, Belgium
Antwerp University Hospital
Edegem, Belgium
Clinique de l'Europe
Amiens, France
CHU Hopitaux de Bordeaux - Hôpital Saint-André
Bordeaux, France
CHU de Lyon - Louis Pradel Hospital
Bron, France
Centre Hospitalier Intercommunal de Créteil
Créteil, France
Hôpital Albert Calmette
Lille, France
L'Institut Paoli - Calmettes
Marseille, France
CHU de Nantes - Hôpital Nord Laennec
Nantes, France
Marie Wislez
Paris, France
Hôpital Bichat - Claude-Bernard
Paris, France
Hôpital Européen Georges Pompidou (HEGP)
Paris, France
CHU de Poitiers
Poitiers, France
Hôpital d'Instruction des Armées Bégin
Saint-Mandé, France
Sana Klinikum Offenbach GmbH
Offenbach, Germany
Krankenhaus Nordwest
Frankfurt am Main, Hesse, Germany
Azienda Ospedaliero-Universitaria di Bologna Policlinico S. Orsola-Malpighi
Bologna, Italy
ASST degli Spedali Civili di Brescia
Brescia, Italy
Fondazione IRCCS Istituto Nazionale dei Tumori
Milan, Italy
ASST Grande Ospedale Metropolitano Niguarda
Milan, Italy
Azienda Ospedaliero - Universitaria San Luigi Gonzaga
Orbassano, Italy
Azienda Ospedaliera Universitaria San Giovanni di Dio e Ruggi d'Aragona
Salerno, Italy
Azienda Ospedaliera Universitaria Integrata Verona - Ospedale Borgo Trento
Verona, Italy
Istituto Nazionale dei Tumori Regina Elena
Roma, Rome, Italy
Netherlands Cancer Institute
Amsterdam, Netherlands
University Medical Center Groningen
Groningen, Netherlands
Erasmus Medical Center
Rotterdam, Netherlands
National Cancer Centre of Singapore
Singapore, Singapore
Gachon University Gil Hospital
Incheon, South Korea
Samsung Medical Center
Seoul, South Korea
Seoul National University Hospital
Seoul, South Korea
Severance Hospital - Yonsei Cancer Center
Seoul, South Korea
The Catholic University of Korea, Seoul St. Mary's Hospital
Seoul, South Korea
The Catholic University of Korea, St. Vincent's Hospital
Suwon, Gyeonggi-do, South Korea
Hospital HM Delfos
Barcelona, Spain
Hospital de la Santa Creu i Sant Pau
Barcelona, Spain
Showing 40 of 51 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.